Conexeu Sciences INC

Market Movers (8-K)

NASDAQ
CNXU
Conexeu Sciences INC
8-K: Conexeu Sciences Completes Preclinical Study for CXU Platform
Conexeu Sciences announced the completion of its 12-month P.R.O.O.F preclinical study for its CXU platform, demonstrating tissue restoration and injectable performance, paving the way for a planned 510(k) submission in wound care by Q1 2027.

Schedule 13G - Passive Investments

NASDAQ
CNXU
Conexeu Sciences INC
SCHEDULE: Michael G. Wright Discloses Stake in Conexeu Sciences
Michael G. Wright has reported beneficial ownership of 12.1% of Conexeu Sciences Inc. common stock as of June 30, 2026.
NASDAQ
CNXU
Conexeu Sciences INC
SCHEDULE: Paisley Capital Holdings Discloses 6.7% Stake in Conexeu Sciences
Paisley Capital Holdings Corp. has reported beneficial ownership of 1,800,000 shares, representing 6.7% of the common stock of Conexeu Sciences Inc.